Forward catalyst · INTS

pazopanib

Sponsor INTS · listed as INTS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

pazopanib is a clinical-stage drug asset sponsored by INTS, listed as INTS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 30, 2026 (day precision, medium confidence), tied to trial NCT03592472. The asset is in Phase 3 and currently recruiting, studied in Renal Cell Carcinoma. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2026-12-30

As disclosedDec 30, 2026

Date precisionday

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT03592472

PhasePHASE3

StatusRECRUITING

Lead sponsorXynomic Pharmaceuticals, Inc.

Listed asINTS

Condition(s)Renal Cell Carcinoma

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More INTS catalysts